格隆汇9月26日丨联盛化学(301212.SZ)在投资者互动平台表示，公司的GBL、NMP、IPA等产品属于湿 电子化学品的范畴，应用领域触及显示面板、半导体、太阳能电池等产品的显影、蚀刻、清洗等制造工 艺。公司的产品暂时没有直接与终端光伏储能客户合作，具体下游客户是否有相关应用，建议关注下游 环节的披露信息。 ...

深圳商报·读创客户端记者 张弛 9月19日，证监会浙江证监局发布公告，因涉闲置募集资金理财违规，决定对联盛化学(301212)及公司 董事长牟建宇、总经理俞快、时任财务总监戴素君、董事会秘书周正英采取出具警示函的监管措施。 浙江证监局认定，上述行为违反相关规定。联盛化学董事长牟建宇、总经理俞快、时任财务总监戴素 君、董事会秘书周正英对上述违规行为承担主要责任。根据《上市公司信息披露管理办法》（证监会令 第182号）第五十二条规定，浙江证监局决定，对上述责任人分别采取出具警示函的监督管理措施，并 记入证券期货市场诚信档案。 9月10日，联盛化学公告称，公司及相关当事人因同一事由收到深圳证券交易所监管函。 公开信息显示，联盛化学成立于2007年10月，是一家特种精细化工领域的高新技术企业，2022年4月在 创业板上市，公司主营产品广泛应用于医药、农药、电子化学品、化妆品以及半导体、锂电池等新兴领 域。 业绩方面，联盛化学2025年半年度报告披露，公司上半年实现营业总收入3.43亿元，同比增长13.95%； 归母净利润1802.17万元，同比增长9.61%；扣非净利润1604.35万元，同比增长11.35%；经营活 ...

Group 1 - The core viewpoint of the news is that Liansheng Chemical experienced a decline in stock price and significant changes in financing activities on September 18, with a net financing outflow of 449.16 thousand yuan [1] - On September 18, Liansheng Chemical's stock price fell by 3.21%, with a trading volume of 41.93 million yuan [1] - The total financing and securities balance for Liansheng Chemical as of September 18 is 47.11 million yuan, which accounts for 1.66% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of June 30, Liansheng Chemical had 8,697 shareholders, an increase of 2.52% from the previous period, with an average of 10,779 circulating shares per person, up by 238.68% [2] - For the first half of 2025, Liansheng Chemical reported a revenue of 34.3 million yuan, representing a year-on-year growth of 13.95%, and a net profit attributable to shareholders of 18.02 million yuan, up by 9.61% [2] Group 3 - Since its A-share listing, Liansheng Chemical has distributed a total of 97.52 million yuan in dividends, with 75.38 million yuan distributed over the past three years [3]

Core Viewpoint - Liansheng Chemical (301212.SZ) has received a regulatory letter from the Shenzhen Stock Exchange due to violations related to the management of idle raised funds, but the company claims that this issue has not affected its daily operations [1][2]. Group 1: Regulatory Issues - The company has been found to have multiple violations in its management of idle raised funds, including purchasing financial products before the approval period and exceeding the authorized purchase amount [2]. - Key personnel, including the chairman and general manager, have also faced regulatory measures for failing to fulfill their duties and obligations [2]. Group 2: Fundraising and Investment Projects - Liansheng Chemical was listed on the Shenzhen Stock Exchange in April 2022, raising a total of 8.01 billion yuan, with net proceeds of 7.27 billion yuan after deducting issuance costs [3]. - The raised funds are primarily allocated to two major projects aimed at expanding the company's business scale and improving production efficiency, with expected production commencement in mid-2026 [3]. Group 3: Financial Performance - Since its listing, the company has experienced significant fluctuations in its financial performance, with 2022 revenues of 1.041 billion yuan, a 24.98% increase year-on-year, and a net profit of 183 million yuan, up 106.69% [4]. - However, revenues declined to 662 million yuan in 2023, a 36.41% decrease, and further dropped to 632 million yuan in 2024, reflecting ongoing challenges in the market [4][5]. - The first half of 2025 showed signs of recovery, with revenues of 343 million yuan, a 13.95% increase, and a net profit of 18 million yuan, up 9.61% [4][5]. Group 4: Industry Context - The chemical industry is facing challenges such as intensified competition, rising raw material costs, and insufficient effective demand, which have contributed to the company's recent performance issues [5]. - Despite a slight recovery in the first half of 2025, the overall industry remains under pressure, with a reported 1.4% increase in revenue but a 9.0% decrease in profit for the chemical raw materials and products manufacturing sector [5].

证券之星消息，9月11日联盛化学公开信息显示，浙江联盛化学股份有限公司，董事长牟建宇、总经理 俞快、非独立董事周正英、戴素君因信息披露违规,未依法履行其他职责,提前使用募集资金被中国证券 监督管理委员会浙江监管局出具警示函。 详细违规行为如下： 我局在对浙江联盛化学股份有限公司(以下简称公司)现场检查中发现,公司闲置募集资金理财购买时间早 于审议授权期限,购买金额超过审议授权额度,2023年半年度、2023年年度、2024年半年度、2024年年度 募集资金存放与使用情况的专项报告中购买大额存单金额披露不准确。 处罚决定如下： 采取出具警示函的监督管理措施,并记入证券期货市场诚信档案 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Points - Liansheng Chemical (301212.SZ) received a warning letter from the Zhejiang Securities Regulatory Bureau due to violations related to the management and use of raised funds [1][2] - The company was found to have purchased financial products with idle raised funds before the authorization period and exceeded the authorized amount [1] - The special reports on the use of raised funds for the first half of 2023, the full year of 2023, the first half of 2024, and the full year of 2024 contained inaccurate disclosures regarding the purchase of large time deposits [1] Regulatory Violations - The company's actions violated the "Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies" and the "Administrative Measures for Information Disclosure of Listed Companies" [2] - Key executives, including the chairman, general manager, former financial director, and board secretary, were held primarily responsible for the violations [2] - The Zhejiang Securities Regulatory Bureau decided to issue warning letters to the company and the related personnel, which will be recorded in the integrity archives of the securities and futures market [2]

公司上述行为违反了《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》(证监会 公告〔2022〕15号)第十二条第一款、《上市公司信息披露管理办法》(证监会令第182号)第三条第一款 规定。公司董事长牟建宇、总经理俞快、时任财务总监戴素君、董事会秘书周正英违反《上市公司信息 披露管理办法》(证监会令第182号)第四条、第五十一条规定，对上述违规行为承担主要责任。根据 《上市公司信息披露管理办法》(证监会令第182号)第五十二条规定，浙江证监局定对公司及相关人员 分别采取出具警示函的监督管理措施，并记入证券期货市场诚信档案。 浙江证监局在对浙江联盛化学股份有限公司(以下简称公司)现场检查中发现，公司闲置募集资金理财购 买时间早于审议授权期限，购买金额超过审议授权额度，2023年半年度、2023年年度、2024年半年度、 2024年年度募集资金存放与使用情况的专项报告中购买大额存单金额披露不准确。 智通财经APP讯，联盛化学(301212.SZ)发布公告，公司于近日收到中国证券监督管理委员会浙江监管局 (以下简称"浙江证监局")下发的《关于对浙江联盛化学股份有限公司及相关人员采取出具警示函措施的 决 ...

证券代码：301212 证券简称：联盛化学 公告编号：2025-035 浙江联盛化学股份有限公司 关于公司及相关人员收到浙江证监局警示函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江联盛化学股份有限公司于近日收到中国证券监督管理委员会浙江监管 局（以下简称"浙江证监局"）下发的《关于对浙江联盛化学股份有限公司及相 关人员采取出具警示函措施的决定》（〔2025〕191 号）（以下简称"警示函"）， 现将具体情况公告如下： 一、警示函的内容 浙江联盛化学股份有限公司 董事会 我局在对浙江联盛化学股份有限公司（以下简称公司）现场检查中发现，公 司闲置募集资金理财购买时间早于审议授权期限，购买金额超过审议授权额度， 2023 年半年度、2023 年年度、2024 年半年度、2024 年年度募集资金存放与使用 情况的专项报告中购买大额存单金额披露不准确。 公司上述行为违反了《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》（证监会公告〔2022〕15 号）第十二条第一款、《上市公 司信息披露管理办法》（证监会令第 182 号）第三条第 ...

每经AI快讯，2025年9月10日，深交所向浙江联盛化学（SZ 301212，收盘价：27.41元）股份有限公司 及相关当事人发出监管函：根据浙江证监局《关于对浙江联盛化学股份有限公司及相关人员采取出具警 示函措施的决定》查明的事实，你们存在以下违规行为：你公司闲置募集资金理财购买时间早于审议授 权期限，购买金额超过审议授权额度，2023年半年度、2023年年度、2024年半年度、2024年年度募集资 金存放与使用情况的专项报告中购买大额存单金额披露不准确。你公司的相关行为违反了本所《创业板 股票上市规则》第1.4条、第5.1.1条和《上市公司自律监管指引第2号——创业板上市公司规范运作》第 1.3条、第6.3.5条的规定。牟建宇作为你公司董事长、俞快作为你公司总经理、戴素君作为你公司时任 财务总监、周正英作为你公司董事会秘书，未能恪尽职守、履行诚信勤勉义务，违反了《创业板股票上 市规则》第1.4条、第4.2.2条、第5.1.2条的规定。请你们充分重视相关问题，吸取教训，及时整改，杜 绝相关问题的再次发生。 2024年1至12月份，联盛化学的营业收入构成为：精细化工业占比100.0%。 截至发稿，联盛化学市值 ...

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Liansheng Chemical, indicating a significant level of financing activity and a stable growth in revenue and profit [1][2]. - On August 28, Liansheng Chemical's stock fell by 1.56%, with a trading volume of 57.99 million yuan. The financing buy-in amount was 7.56 million yuan, while the financing repayment was 4.68 million yuan, resulting in a net financing buy-in of 2.88 million yuan [1]. - As of August 28, the total balance of margin trading for Liansheng Chemical was 52.19 million yuan, accounting for 1.82% of its market capitalization, which is above the 90th percentile level over the past year [1]. Group 2 - As of June 30, the number of shareholders for Liansheng Chemical was 8,697, an increase of 2.52% from the previous period. The average circulating shares per person rose to 10,779 shares, an increase of 238.68% [2]. - For the first half of 2025, Liansheng Chemical reported a revenue of 343 million yuan, representing a year-on-year growth of 13.95%. The net profit attributable to the parent company was 18.02 million yuan, reflecting a year-on-year increase of 9.61% [2]. - Since its A-share listing, Liansheng Chemical has distributed a total of 97.52 million yuan in dividends, with 75.38 million yuan distributed over the past three years [3].